Glass-contacted human serum infused into animals induces stasis thrombi similar to red thrombi observed in man (1) . The activity in glass-contacted human serum initiating these thrombi has been termed serum thrombotic accelerator (STA) activity (2) . It can be measured by a rabbit assay (3) and is distinct from tissue thromboplastin, platelets, and thrombin (4, 5) . Silicone-processed ("intact") serum from normal subjects and glasscontacted serum from patients deficient in coagulation Factors XII (Hageman), XI (PTA), or IX (PTC) develop little, if any, STA activity (2, 5) . In contrast, glass-contacted serum from patients with other clotting defects develops normal STA activity (2) . These observations led to the hypothesis that elaboration of STA activity was mediated through activation of the initial three procoagulants (Factors XII, XI, and IX) involved in the in vitro formation of intrinsic, or blood, thromboplastin (1) .
The role of Factor IX in the elaboration of STA activity has been recently brought under fresh scrutiny. Preparations rich in activated Factor XI (activation product, AP) and essentially devoid of other known clotting factors, have been found to be thrombogenic (6) . This is true whether the AP is isolated from normal or Factor IX-deficient plasma or serum (6) . As a result of these studies, it has been suggested that the thrombogenic activity originally described as STA activity is attributable to AP and that STA activity, in fact, represents the in vivo manifestation of AP (6) .
To examine the validity of this thesis, the thrombogenic activity of serum obtained from patients with established heredofamilial defects of Factor * Submitted for publication June 21, 1963 ; accepted October 3, 1963. This study was supported by research grants H-1027 and HE-6316 from the National Institutes of Health and by a grant-in-aid from the American Heart Association.
IX was compared with that of serum from normal subjects by a standard bioassay, and these in vivo data were correlated with in vitro assays for AP and Factor IX. The experiments reported here demonstrate that although the elaboration of STA activity is dependent on the contact activation steps involved in the formation of intrinsic thromboplastin, STA activity cannot be equated with the activity measured by the one-stage partial thromboplastin assay of AP.
Methods
A. Collection of serum. Human serum was collected by venipuncture with a two-syringe technic, using silicone-coated1 syringes and monocoated2 needles. Blood to be assayed as "intact serum" was 'immediately transferred to silicone-coated tubes. Blood to be assayed as "contact serum" was immediately transferred to new, uncoated glass tubes before coagulation ensued. The processing of all blood samples was performed in tubes covered with parafilm.3 All serum samples were allowed to stand for 2 hours at room temperature and then for 18 hours at 40 C. The blood samples were subsequently centrifuged for 20 minutes at 2,500 X g, and the serum removed. Several serum samples, collected initially as contact serum, were also exposed either to kaolin (0.5 mg per ml) or Celite4 (30 mg per ml) for 10 minutes on an electric mixer at room temperature, and the powders were removed by centrifugation at 10,000 X g at 4°C for 5 minutes and by subsequent filtration through Whatman 1 filter paper. All serum samples were stored in 3-ml samples at -200 C. Subsequent manipulations were performed with siliconized equipment throughout. Individual tubes were defrosted only once, immediately before testing for in vivo and in vitro assays.
B. Thrombosis assay. Thrombus formation was measured by a standard rabbit assay (3) (14) , this "exhausted" plasma supported normal thromboplastin generation.
AP-rich eluates were prepared from normal human plasma, according to the method of Henderson and Rapaport (6) .
Preformed AP was assayed by a modification of the technic of Henderson and Rapaport (6) . The test was performed by adding to a siliconized tube in order: 0.1 ml of exhausted plasma, 0.1 ml of a commercially prepared partial thromboplastin,5 and 0.1 ml of the substance to be tested-all maintained at melting-ice temperature. The tube was then transferred to a water bath at 370 C. After 30 seconds, 0.1 ml of the 30 mM calcium chloride solution was added and a stopwatch was simultaneously started. After 50 seconds, the tube was tilted gently every 5 seconds until a fibrin gel formed, at which moment the clotting time was recorded. Under conditions of glass-contact activation, individually processed samples of serum exhibited a wide range of preformed AP comparable to that described by other investigators (6) .
A calibration curve ( Figure 1 ) was prepared with a standard AP-rich eluate diluted serially with dilution fluid II of Waaler (15) , to give an arbitrary reference standard for AP. With this system, it was possible to 5Thrombofax reagent, Ortho Research Laboratory, Raritan, N. J., supplied through the courtesy of Dr. Heron Singher. NAL PLASMA VOLUME. 100%o activity is defined by the clotting time (in seconds) of a system containing 0.1 ml reference eluate, 0.1 ml exhausted plasma, 0.1 ml partial thromboplastin, and 0.1 ml 30 mM CaCLi.
compare plasma, serum, and isolated blood fractions for AP activity, since the exhausted plasma supplied all known coagulation factors other than Factors XII and XI.
To confirm that the exhausted plasma was in fact depleted of Factors XII and XI, normal, Factor XII-deficient, and Factor XI-deficient intact plasmas were assayed for AP before and after activation by kaolin powder (Table   I) . Factor IX activity in serum was measured in a partial thromboplastin time assay that utilized as a substrate hen plasma, devoid of Factors XII, XI, and IX (13) , and AP-rich eluates free of measurable quantities of all other procoagulants. To obtain such eluates for use in this test, the AP eluates prepared as described above were adsorbed with barium sulfate, 100 mg per ml of eluate for 10 minutes on an electric mixer, to remove residual traces of Factors II, VII, IX, and X. This procedure, as noted by Waaler, also results in a marked loss of AP activity (15) . The 10% AP activity remaining, however, was sufficient to produce a linear dilution curve in the Factor IX assay (Figure 2 ). The test is performed (using dilution fluid II as diluent) by adding to a siliconized tube in order: 0.1 ml of the test serum diluted 1: 5; 0.1 ml of hen plasma collected on 3.8% sodium citrate, diluted 1: 2; 0.1 ml of commercial partial thromboplastin (Thrombofax) diluted 1:10; and 0. When normal human contact serum was assayed, sufficient AP was supplied by the test serum to make the addition of the AP eluates to the hen plasma unnecessary (Table II) . For the calibration curves employing serial dilutions of normal glass-contacted human serum, however, the addition of AP-rich eluates was necessary to render the system critical only for Factor IX. Similarly, the addition of the AP eluate to the test system was necessary for the construction of calibration curves of intact plasma Factor IX activity to assess the Factor IX content of exhausted plasma (Table II) . AP elu-6J. T. Baker Chemical Co., Phillipsburg, N. J. Figure 2 ates were routinely added to all Factor IX assays to insure that the Factor IX level would be independent of variations in the AP levels of the serum or plasma tested.
Thrombic activity was measured by the technic of Johnson and Seegers (16) .
Results
The results of the infusions into rabbits of glasscontacted normal and Factor IX-deficient human serum and of the in vitro assays for AP and Factor IX are shown in Table III Kaolin activated Normal serum Patient 3, Table III Table III. t All values in excess of 1,000 %. Normal subject Patient 3, Table III  4 Table II I (11-13) * Percentage of reference activity. t Bioassay score as in Table III. from Patient 4, whose AP values were almost all below the normal range, was clearly the most thrombogenic of the three Factor IX-deficient sera tested. Although the serum from Patient 4 may be atypical (see Discussion), it is apparent from the data in Table III that the AP level of glass-contacted serum is not an in vitro measure of STA activity. The validity of this conclusion is supported by supplemental experiments in which AP levels and STA activity of normal and Factor IXdeficient serum were determined after exposure of the serum to kaolin or Celite. Although both normal and Factor IX-deficient serum reached equally elevated levels of AP, normal serum, after 10 minutes of vein isolation, was still more thrombogenic than Factor IX-deficient serum (Table IV) . After 15 minutes this difference was no longer apparent.
It is also clear that STA activity cannot be elaborated without prior activation of Factor XI. Thus, intact serum prepared from normal subjects or Factor IX-deficient patients elaborated negligible amounts of AP and induced no thrombosis after 10 minutes of stasis (Table V) .
Discussion
This study was undertaken to determine whether or not STA activity is the in vivo manifestation of AP.
Waaler has shown that the measurement of AP by a one-stage, partial thromboplastin assay reflects contact activation and detects hereditary deficiencies in Factor XII or XI (15) . In addition, he has demonstrated that glass-contacted serum, although rich in AP, elaborates a strikingly higher AP titer after exposure of such serum to substances that provide additional surface area for activation (15) .
The data presented in Table III demonstrate, however, that when serum is exposed to a partially activating surface, such as new, uncoated glass tubes, or even exposed to kaolin or Celite (Table  IV) , the thrombogenic capacity of serum does not correlate with the AP content.
It is true that in the absence of any contact activation, serum infusates are not thrombogenic and are essentially devoid of AP (Table V) (Table III) do show some AP values below the normal range. These discrepancies may derive from the presence in normal serum of activated Factor IX causing an enhanced acceleration of the AP assay and thus a higher apparent AP level in normal serum than in Factor IX-deficient serum. Such an interpretation, although it raises doubts concerning the specificity of the AP assay in serum, only strengthens the thesis that activated Factor XI cannot be equated with STA activity.
Evidence has been recently summarized to support the view that activation of one or more of the initial procoagulants may lead to the formation of fibrin thrombi in areas of retarded blood flow in man (1) . The contribution of stasis to the genesis of these thrombi may be interpreted as the development of an altered physiologic state wherein the activated products of coagulation are protected by a mechanism such as removal of clotting intermediates from the circulation, as suggested by Spaet and Kropatkin (25, 26) . In terms of this concept, the initiation of the stasis thrombus depends on the acceleration of intravascular coagulation to a rate that exceeds the capacity of the compensatory clearance mechanism. The experiments reported in this communication suggest that when human serum is infused, activation of Factor IX or some associated moiety in the infusate may govern a rate-limiting step that determines whether or not stasis thrombi will form. Summary 1) The thrombogenicity of infusions of glasscontacted normal and Factor IX-deficient human serum in rabbits and the activation product (AP) and Factor IX content of these infusates were determined.
2) Glass-contacted Factor IX-deficient serum was markedly less thrombogenic than normal human serum. The thrombogenicity of glass contacted Factor IX-deficient serum did not correlate with its level of AP.
3) Although elaboration of serum thrombotic accelerator (STA) activity is dependent on the contact activation steps involved in the formation of intrinsic thromboplastin, STA activity cannot be equated with the activity measured by the one-stage partial thromboplastin assay of AP. Thus, STA activity is not the in vivo manifestation of AP. 165 4) Factor IX, or an associated moiety in serum, plays a critical role in the formation of stasis thrombi induced by infusions of human serum.
